{"id":"NCT03812224","sponsor":"Amgen","briefTitle":"A Controlled Trial of Erenumab in Migraine Prevention","officialTitle":"A Phase 3 Japanese Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-12","primaryCompletion":"2020-03-16","completion":"2020-11-25","firstPosted":"2019-01-23","resultsPosted":"2021-03-04","lastUpdate":"2024-02-21"},"enrollment":261,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Erenumab","otherNames":["AMG 334","AimovigÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Erenumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to assess the efficacy and safety of erenumab for prevention of migraine in Japanese adults with episodic migraine (EM) and chronic migraine (CM).","primaryOutcome":{"measure":"Change From Baseline in Mean Monthly Migraine Days (MMD) Over Months 4, 5, and 6 of the Double-blind Treatment Period","timeFrame":"4-week baseline period and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment period","effectByArm":[{"arm":"Placebo QM","deltaMin":-1.98,"sd":null},{"arm":"Erenumab 70 mg QM","deltaMin":-3.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":41,"countries":["Japan"]},"refs":{"pmids":["35272533","35201674","34537006","34153117","37597868","37698837"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":131},"commonTop":["Nasopharyngitis","Constipation","Back pain"]}}